collegium
announces
settlement
teva
resolving
er
patent
litigation
stoughton
globe
newswire
collegium
pharmaceutical
nasdaq
coll
specialty
pharmaceutical
company
committed
leader
responsible
pain
management
today
announced
reached
settlement
agreement
teva
pharmaceutical
usa
teva
resolves
patent
litigation
brought
response
teva
abbreviated
new
drug
application
anda
seeking
approval
market
generic
version
xtampza
er
prior
expiration
collegium
applicable
patents
pursuant
terms
settlement
subject
review
federal
trade
commission
department
justice
collegium
grant
teva
license
market
generic
version
xtampza
er
united
states
beginning
september
subject
fda
approval
acceleration
certain
circumstances
result
settlement
teva
agreed
consent
judgment
confirming
proposed
generic
products
infringe
collegium
asserted
patents
patents
valid
enforceable
respect
teva
proposed
generic
products
additional
details
regarding
settlement
confidential
company
committed
leader
responsible
pain
management
seek
deliver
scientific
innovation
differentiated
products
people
suffering
pain
pleased
outcome
anda
settlement
teva
highlights
value
innovation
context
xtampza
er
franchise
said
shirley
kuhlmann
executive
vice
president
general
counsel
collegium
resolution
litigation
reinforces
strength
collegium
intellectual
property
portfolio
includes
orange
patents
covering
xtampza
er
expiries
commitment
innovation
responsible
pain
collegium
pharmaceutical
collegium
specialty
pharmaceutical
company
committed
leader
responsible
pain
management
collegium
headquarters
located
stoughton
massachusetts
information
please
visit
company
website
contact
alex
dasalla
adasalla
